🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

135 results for “formulation” Clear

  1. A study to compare how the body absorbs different formulations of a new medicine, and how food affects drug absorption, in healthy participants

    Janssen-Cilag International N.V.

    Psoriasis

    phase 1 other active

    1 trial

  2. A study to compare the amount of milvexian in blood when given as pediatric and adult tablet formulations, to assess the effect of food intake on the absorption of pediatric milvexian tablet formulation in healthy adult participants and to assess the acceptability of different milvexian formulations.

    Janssen-Cilag International N.V.

    atherothrombotic and thromboembolic disorders

    phase 1 other active

    1 trial

  3. A study to compare two different aramchol formulations in healthy volunteers.

    Galmed Pharmaceuticals

    Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis

    phase 1 other active

    1 trial

  4. A study to investigate the bioavailability of the SAR444656 test formulation and the food effect on the SAR444656 test formulation in healthy adult participants

    Sanofi-aventis Healthcare Pty Ltd

    Healthy Volunteer

    phase 1 other active

    1 trial

  5. A three-part trial in healthy volunteers to find out how long icotrokinra stays in and acts on the body when administered as different tablet formulations and under different food conditions

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  6. A two-part trial in healthy volunteers to find out how long JNJ-77242113 stays in and acts on the body when administered as different tablet formulations and under different food and water conditions, and to assess the acceptability profile (taste, palatability, and smell) of JNJ-77242113 formulations.

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  7. ABI-H2158 Reference Formulation

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  8. AG881 Formulation 1

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  9. AKB-6548 tablet, reference formulation given in the fasted state

    Akebia Europe Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  10. AN OPEN LABEL, TWO PERIODS, TWO SEQUENCES, CROSSOVER, RANDOMIZED MULTIPLE DOSE BIOEQUIVALENCE STUDY OF GUANFACINE 7 MG PROLONGED-RELEASE TABLETS (TEST FORMULATION) VS. EQUAL DOSE OF INTUNIV® PROLONGED-RELEASE TABLETS (REFERENCE FORMULATION) IN HEALTHY MALE VOLUNTEERS UNDER FASTING CONDITIONS

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Study performed on healthy volunteers.

    phase 1 other active

    1 trial

  11. AT-527 Formulation 1

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  12. An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  13. An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  14. Assessment of narrowing of blood vessels after single application of two clascoterone formulations (cream and solution) onto the skin in comparison to three marketed topical corticosteroids

    Cassiopea S.p.A.

    Test of vasocontriction properties for classification of topical steroid potency

    phase 1 other active

    1 trial

  15. Azilsartan (Zhaoke)

    Lee's Pharmaceutical Limited

    Bioequivalence of Two Azilsartan Formulations

    phase 1 small molecule completed

    1 trial

  16. BiiB115 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of BIIB115 drug product minus the active ingredient, BIIB115

    Biogen

    Spinal muscular atrophy

    phase 1 small molecule active

    1 trial

  17. Bioavailability study of stiripentol after single oral administration of two different formulations (capsule and oral suspension) in 24 healthy subjects

    Biocodex

    Dravet syndrome

    phase 1 other active

    1 trial

  18. Bioequivalence clinical trial of two formulations of linagliptin/metformin

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  19. Bioequivalence clinical trial of two formulations of bilastine.

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  20. Bioequivalence clinical trial of two formulations of canagliflozin

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  21. Bioequivalence clinical trial of two formulations of dapagliflozin.

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  22. Bioequivalence clinical trial of two formulations of dapagliflozin/metformin

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  23. Bioequivalence clinical trial of two formulations of dapagliflozin/metformin

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  24. Bioequivalence clinical trial of two formulations of edoxaban.

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources